Genome-wide analysis of androgen receptor binding sites in prostate cancer cells

Experimental and Therapeutic Medicine

Volumn 9, Issue 6, 2015, Pages 2319-2324

  Cheng, Yue ^a   Yu, Pan ^a   Duan, Xiuzhi ^a   Liu, Chunhua ^a   Xu, Siqi ^a   Chen, Yuhua ^a   Tan, Yunnian ^a   Qiang, Yun ^a   Shen, Junfang ^a   Tao, Zhihua ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Androgen receptor; Androgen receptor binding sites; Chromatin immunoprecipitation; High throughput sequencing; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR;

ARTICLE; BINDING SITE; CHROMATIN IMMUNOPRECIPITATION; DNA BINDING MOTIF; GENE IDENTIFICATION; GENE MAPPING; GENE ONTOLOGY; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; PROSTATE CANCER; SEQUENCE ALIGNMENT; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION;

EID: 84928242202     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2406     Document Type: Article

References (30)

1. Suzuki H, Ueda T, Ichikawa T and Ito H: Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer 10: 209-216, 2003.
2. Debes JD and Tindall DJ: Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351: 1488-1490, 2004.
3. Scher HI, Liebertz C, Kelly WK, et al: Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 15: 2928-2938, 1997.
4. Chen CD, Welsbie DS, Tran C, et al: Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39, 2004.
5. Hu R, Dunn TA, Wei S, et al: Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69: 16-22, 2009.
6. Zeng R, Liu Z, Sun Y and Xu C: Differential expression and function of AR isoforms in prostate cancer. Oncol Rep 27: 492-498, 2012.
7. Carver BS, Chapinski C, Wongvipat J, et al: Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19: 575-586, 2011.
8. Richter E, Srivastava S and Dobi A: Androgen receptor and prostate cancer. Prostate Cancer Prostatic Dis 10: 114-118, 2007.
9. Wang Q, Li W, Zhang Y, et al: Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138: 245-256, 2009.
10. Wang Q, Li W, Liu XS, et al: A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 27: 380-392, 2007.
11. Yu J, Yu J, Mani RS, et al: An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17: 443-454, 2010.
12. Jia L, Berman BP, Jariwala U, et al: Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS One 3: e3645, 2008.
13. Xu G, Wu J, Zhou L, et al: Characterization of the small RNA transcriptomes of androgen dependent and independent prostate cancer cell line by deep sequencing. PLoS One 5: e15519, 2010.
14. Tewari AK, Yardimci GG, Shibata Y, et al: Chromatin accessibility reveals insights into androgen receptor activation and transcriptional specificity. Genome Biol 13: R88, 2012.
15. Zhang Y, Liu T, Meyer CA, et al: Model-based analysis of ChIP-Seq (MACS). Genome Biol 9: R137, 2008.
16. Bailey TL and Elkan C: Fitting a mixture model by expectation maximization to discover motifs in biopolymers. Proc Int Conf Intell Syst Mol Biol 2: 28-36, 1994.
17. Ma W, Noble WS and Bailey TL: Motif-based analysis of large nucleotide data sets using MEME-ChIP. Nat Protoc 9: 1428-1450, 2014.
18. Ashburner M, Ball CA, Blake JA, et al; The Gene Ontology Consortium: Gene ontology: tool for the unification of biology. Nat Genet 25: 25-29, 2000.
19. Tomlins SA, Mehra R, Rhodes DR, et al: Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39: 41-51, 2007.
20. Vander Griend DJ, D'Antonio J, Gurel B, Antony L, Demarzo AM and Isaacs JT: Cell-autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells. Prostate 70: 90-99, 2010.
21. Kokontis JM, Hsu S, Chuu CP, Dang M, Fukuchi J, Hiipakka RA and Liao S: Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity. Prostate 65: 287-298, 2005.
22. Attard G, Richards J and de Bono JS: New strategies in metastatic prostate cancer: Targeting the androgen receptor signaling pathway. Clin Cancer Res 17: 1649-1657, 2011
23. Lupien M, Eeckhoute J, Meyer CA, et al: FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132: 958-970, 2008.
24. Zinzen RP, Girardot C, Gagneur J, Braun M and Furlong EE: Combinatorial binding predicts spatio-temporal cis-regulatory activity. Nature 462: 65-70, 2009.
25. Liu T, Gao H, Yang M, Zhao T, Liu Y and Lou G: Correlation of TNFAIP8 overexpression with the proliferation, metastasis, and disease-free survival in endometrial cancer. Tumour Biol 35: 5805-5814, 2014.
26. Liu T, Xia B, Lu Y, Xu Y and Lou G: TNFAIP8 overexpression is associated with platinum resistance in epithelial ovarian cancers with optimal cytoreduction. Hum Pathol 45: 1251-1257, 2014.
27. Zhang C, Kallakury BV, Ross JS, et al: The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence. Int J Cancer 133: 31-42, 2013.
28. Chase D, McLauchlan G, Eckersall PD, Pratschke J, Parkin T and Pratschke K: Acute phase protein levels in dogs with mast cell tumours and sarcomas. Vet Rec 170: 648, 2012.
29. Papadia C, Louwagie J, Del Rio P, et al: FOXE1 and SYNE1 genes hypermethylation panel as promising biomarker in colitis-associated colorectal neoplasia. Inflamm Bowel Dis 20: 271-277, 2014.
30. Shi S, Zhou B, Wang Y, et al: Genetic variation in RTN4 3'-UTR and susceptibility to cervical squamous cell carcinoma. DNA Cell Biol 31: 1088-1094, 2012.